RSS 1.0
Scholarship & History
The UMB Digital Archive is a service of the Health Sciences and Human Services Library (HS/HSL) that collects, preserves, and distributes the academic works of the University of Maryland, Baltimore. It is a place that digitally captures the historical record of the campus.
Communities in UMB Digital Archive
Select a community to browse its collections.
Recently Added
-
Anti-SARS-CoV-2 immune responses in patients receiving an allogeneic stem cell or organ transplantfirst_pagesettings Open AccessCase Report Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant by Djordje Atanackovic 1,2,*,†,Tim Luetkens 1,2,†,Stephanie V. Avila 1,Nancy M. Hardy 1,Forat Lutfi 3,Gabriela Sanchez-Petitto 3,Erica Vander Mause 1,Nicole Glynn 1,Heather D. Mannuel 4,5,Hanan Alkhaldi 3,Kim Hankey 1,John Baddley 6OrcID,Saurabh Dahiya 1,† andAaron P. Rapoport 1,† 1 Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA 2 Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA 3 University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA 4 Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA 5 Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, USA 6 Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA * Author to whom correspondence should be addressed. † Both authors contributed equally. Academic Editor: Ralph A. Tripp Vaccines 2021, 9(7), 737; https://doi.org/10.3390/vaccines9070737 Received: 26 May 2021 / Revised: 17 June 2021 / Accepted: 29 June 2021 / Published: 3 July 2021 (This article belongs to the Section COVID-19 Vaccines and Vaccination) Download PDF Browse Figures Citation Export Abstract Patients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and solid organ transplants, requires intensive immunosuppressive prophylaxis, which may further undermine the development of a protective vaccine-induced anti-viral immunity. Herein, we report on short- and long-term antiviral immune responses in two peri-stem cell transplant recipients and a third patient who received a COVID-19 vaccination after kidney transplantation. Our data indicate that: (1) patients post-alloSCT may be able to mount an anti-COVID-19 immune response; however, a sufficient time interval between transplant and exposure may be of critical importance; (2) alloSCT recipients with preexisting anti-SARS-CoV-2 immunity are at risk for losing protective humoral immunity following transplantation, particularly if the stem-cell donor lacks antiviral immunity, e.g., vaccine-derived immunity; and (3) some post-transplant patients are completely unable to build an immune response to a COVID-19 vaccine, perhaps based on the prophylactic suppression of T cell immunity.
-
Opioids and the Workplace: Prevention and ResponsePowerPoint presentation discussing the scope and severity of the opioid crisis, summarizing the relationship between workplace injuries and illnesses, working conditions, and opioid use disorder. Also included is a link to the NIEHS "Opioids & Substance Use: Workplace Prevention & Response" web page.
-
Addressing Opioid Overdose Deaths in the WorkplaceOn average, 115 Americans die every day from an opioid overdose, according to 2017 data from Centers for Disease Control (CDC). Since then, the United States has experienced a surge of overdose deaths during the 2019 novel coronavirus disease (COVID-19) pandemic, according to a CDC health advisory (https://emergency.cdc.gov/han/2020/ha...) issued in December of 2020. Some states have reported an increase in opioid deaths as high as 98%. Overdoses are becoming increasingly common in the workplace. Naloxone can reverse many of the potentially fatal side effects of an opioid overdose. Having naloxone on hand can provide a tool that a workplace can use while waiting on first responders to arrive on the scene. National Institute for Occupational Safety and Health (NIOSH) developed this video based on our fact sheet (https://www.cdc.gov/niosh/docs/2019-1...) to help employers decide if having naloxone available is right for their workplace. It provides a series of steps for employers to consider when deciding whether their workplaces should make the overdose reversal medication available on-site in the event of an overdose. It also gives employers and workers information on how to implement and maintain a workplace naloxone program. Overdose deaths from opioids is a serious health issue in the United States. Naloxone is an effective drug for reversing opioid overdoses. Consider establishing a naloxone program in your workplace.
-
Isolated Antineutrophil Cytoplasmic Antibody-Associated Coronary Vasculitis and ValvulitisA 30-year-old woman presented with angina pectoris. Coronary angiography revealed severe stenosis in the left main and right coronary arteries that did not improve with intracoronary nitroglycerin. Coronary computed tomography angiography and positron emission tomography revealed coronary ostia inflammation and aortic root fat stranding. She was diagnosed with vasculitis and valvulitis and received immunotherapy and coronary bypass. (Level of Difficulty: Advanced.).
